Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Host cell mTORC1 is required for HCV RNA replication.

Stöhr S, Costa R, Sandmann L, Westhaus S, Pfaender S, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, von Hahn T, Ciesek S.

Gut. 2016 Dec;65(12):2017-2028. doi: 10.1136/gutjnl-2014-308971. Epub 2015 Aug 14.

2.

Effects of the Mammalian Target of Rapamycin Inhibitor Everolimus on Hepatitis C Virus Replication In Vitro and In Vivo.

Frey A, Ecker EM, Piras-Straub K, Walker A, Hofmann TG, Timm J, Singer BB, Gerken G, Herzer K.

Transplant Proc. 2017 Oct;49(8):1947-1955. doi: 10.1016/j.transproceed.2017.04.012.

PMID:
28923653
3.

Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.

Zhang X, Wang X, Xu T, Zhong S, Shen Z.

Tumour Biol. 2015 Jul;36(7):5273-81. doi: 10.1007/s13277-015-3187-7. Epub 2015 Feb 11.

PMID:
25666752
4.

Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.

Liu WL, Yang HC, Hsu CS, Wang CC, Wang TS, Kao JH, Chen DS.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14799-14804. doi: 10.1073/pnas.1618517114. Epub 2016 Dec 6.

5.

Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner.

Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, Tsai WL, Hyppolite G, Chung RT.

J Virol. 2010 Jun;84(12):6060-9. doi: 10.1128/JVI.02484-09. Epub 2010 Apr 7.

6.

Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.

Huang H, Kang R, Wang J, Luo G, Yang W, Zhao Z.

Autophagy. 2013 Feb 1;9(2):175-95. doi: 10.4161/auto.22791. Epub 2012 Nov 20.

7.

Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication.

Kuss-Duerkop SK, Wang J, Mena I, White K, Metreveli G, Sakthivel R, Mata MA, Muñoz-Moreno R, Chen X, Krammer F, Diamond MS, Chen ZJ, García-Sastre A, Fontoura BMA.

PLoS Pathog. 2017 Sep 27;13(9):e1006635. doi: 10.1371/journal.ppat.1006635. eCollection 2017 Sep.

8.

Glucocorticosteroids increase cell entry by hepatitis C virus.

Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T.

Gastroenterology. 2010 May;138(5):1875-84. doi: 10.1053/j.gastro.2010.02.004. Epub 2010 Feb 10.

PMID:
20152835
9.

Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.

Ito M, Yurube T, Kakutani K, Maeno K, Takada T, Terashima Y, Kakiuchi Y, Takeoka Y, Miyazaki S, Kuroda R, Nishida K.

Osteoarthritis Cartilage. 2017 Dec;25(12):2134-2146. doi: 10.1016/j.joca.2017.08.019. Epub 2017 Sep 6.

10.

Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.

Moorman NJ, Shenk T.

J Virol. 2010 May;84(10):5260-9. doi: 10.1128/JVI.02733-09. Epub 2010 Feb 24.

11.

Insulin-induced mTOR activity exhibits anti-hepatitis C virus activity.

Muraoka T, Ichikawa T, Taura N, Miyaaki H, Takeshita S, Akiyama M, Miuma S, Ozawa E, Isomoto H, Takeshima F, Nakao K.

Mol Med Rep. 2012 Feb;5(2):331-5. doi: 10.3892/mmr.2011.662. Epub 2011 Nov 3.

PMID:
22052332
12.

[Inhibition of hepatitis C virus replication by mycophenolic acid in hepatocytes].

Chen H, Ye L, Su JM, Li Y, Zeng JR, Huo WZ.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Feb;27(1):35-8. Chinese.

PMID:
23855126
13.

Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.

Walker NM, Belloli EA, Stuckey L, Chan KM, Lin J, Lynch W, Chang A, Mazzoni SM, Fingar DC, Lama VN.

J Biol Chem. 2016 Mar 18;291(12):6262-71. doi: 10.1074/jbc.M115.672170. Epub 2016 Jan 11.

14.

Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes.

Liu JP, Ye L, Wang X, Li JL, Ho WZ.

Transpl Infect Dis. 2011 Feb;13(1):24-32. doi: 10.1111/j.1399-3062.2010.00556.x. Epub 2010 Oct 7.

15.
16.

mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.

Li J, Liu J, Song J, Wang X, Weiss HL, Townsend CM Jr, Gao T, Evers BM.

Am J Physiol Cell Physiol. 2011 Jul;301(1):C213-26. doi: 10.1152/ajpcell.00067.2011. Epub 2011 Apr 20.

17.

Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.

Wang X, Lai P, Zhang Z, Huang M, Wang L, Yin M, Jin D, Zhou R, Bai X.

Oncol Rep. 2014 Jul;32(1):382-8. doi: 10.3892/or.2014.3182. Epub 2014 May 15.

PMID:
24840134
19.

mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.

Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F.

J Endocrinol. 2013 Jan 2;216(1):21-9. doi: 10.1530/JOE-12-0351. Print 2013 Jan.

PMID:
23092880
20.

Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells.

Ye L, Li J, Zhang T, Wang X, Wang Y, Zhou Y, Liu J, Parekh HK, Ho W.

Virus Res. 2012 Sep;168(1-2):33-40. doi: 10.1016/j.virusres.2012.06.009. Epub 2012 Jun 21.

Supplemental Content

Support Center